Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
연구 개요
This is a Phase 1b, open-label study evaluating Venetoclax in combination with intensive induction and consolidation chemotherapy in previously untreated, adult patients with acute myeloid leukemia. In Part 1, the dose escalation phase, the safety and tolerability of the combination with Venetoclax at different doses and duration will inform the appropriate dose(s) and regimen(s) for Part 2. In Part 2, the dose expansion phase, a maximum of 28 additional patients will be randomized 1:1 to the MTD determined in Part 1 and the starting dose (assuming the MTD is not the starting dose), to further evaluate the safety and efficacy of the study drug combination.
- 스폰서
- 협력: 애브비
- 적응증
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- 중재
- Venetoclax Oral Tablet, Daunorubicin, Cytarabine
- 목표 등록
- 99명
- 시작일
- 2022-05-25
- 완료(예정)
- 2028-12-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.